Literature DB >> 29264942

MethSurv: a web tool to perform multivariable survival analysis using DNA methylation data.

Vijayachitra Modhukur1, Tatjana Iljasenko1, Tauno Metsalu1, Kaie Lokk2, Triin Laisk-Podar3,4, Jaak Vilo1,5.   

Abstract

AIM: To develop a web tool for survival analysis based on CpG methylation patterns. MATERIALS &
METHODS: We utilized methylome data from 'The Cancer Genome Atlas' and used the Cox proportional-hazards model to develop an interactive web interface for survival analysis.
RESULTS: MethSurv enables survival analysis for a CpG located in or around the proximity of a query gene. For further mining, cluster analysis for a query gene to associate methylation patterns with clinical characteristics and browsing of top biomarkers for each cancer type are provided. MethSurv includes 7358 methylomes from 25 different human cancers.
CONCLUSION: The MethSurv tool is a valuable platform for the researchers without programming skills to perform the initial assessment of methylation-based cancer biomarkers.

Entities:  

Keywords:  Cox Proportional-Hazards; DNA methylation; Illumina 450 K; Kaplan–Meier; TCGA; biomarkers; cancer survival analysis; clustering; epigenetics; prognosis

Mesh:

Substances:

Year:  2017        PMID: 29264942     DOI: 10.2217/epi-2017-0118

Source DB:  PubMed          Journal:  Epigenomics        ISSN: 1750-192X            Impact factor:   4.778


  138 in total

1.  High expression of Ran binding protein 1 predicts poor outcomes in hepatocellular carcinoma patients: a Cancer Genome Atlas database analysis.

Authors:  Zhengxiao Wei; Xiaoqiong Duan; Qi Li; Qingfeng Li; Yu Wang
Journal:  J Gastrointest Oncol       Date:  2021-12

2.  DNA methylation-based prognostic biomarkers of acute myeloid leukemia patients.

Authors:  Linjun Hu; Yuling Gao; Zhan Shi; Yang Liu; Junjun Zhao; Zunqiang Xiao; Jiayin Lou; Qiuran Xu; Xiangmin Tong
Journal:  Ann Transl Med       Date:  2019-12

Review 3.  APC Promoter Methylation in Gastrointestinal Cancer.

Authors:  Lila Zhu; Xinyu Li; Ying Yuan; Caixia Dong; Mengyuan Yang
Journal:  Front Oncol       Date:  2021-04-23       Impact factor: 6.244

4.  The CSRNP Gene Family Serves as a Prognostic Biomarker in Clear Cell Renal Cell Carcinoma.

Authors:  Huaru Zhang; Xiaofu Qiu; Guosheng Yang
Journal:  Front Oncol       Date:  2021-03-31       Impact factor: 6.244

5.  Identification and assessment of PLK1/2/3/4 in lung adenocarcinoma and lung squamous cell carcinoma: Evidence from methylation profile.

Authors:  Sisi Deng; Xiaoli Lu; Zhi Zhang; Rui Meng; Mi Li; Shilin Xia
Journal:  J Cell Mol Med       Date:  2021-06-02       Impact factor: 5.310

6.  ITGA3 Is Associated With Immune Cell Infiltration and Serves as a Favorable Prognostic Biomarker for Breast Cancer.

Authors:  Yue Li; Fan Li; Xiaoyu Bai; Yanlei Li; Chunsheng Ni; Xiulan Zhao; Danfang Zhang
Journal:  Front Oncol       Date:  2021-05-20       Impact factor: 6.244

7.  Early B-cell factors involve in the tumorigenesis and predict the overall survival of gastric cancer.

Authors:  Qing Wang; Jiahong Liang; Xianyu Hu; Songgang Gu; Qiaodong Xu; Jiang Yan
Journal:  Biosci Rep       Date:  2021-07-30       Impact factor: 3.840

8.  Comprehensive Analysis of SFRP Family Members Prognostic Value and Immune Infiltration in Gastric Cancer.

Authors:  Dehua Liu; Chenyu Sun; Nahyun Kim; Chandur Bhan; John Pocholo Whitaker Tuason; Yue Chen; Shaodi Ma; Yuting Huang; Ce Cheng; Qin Zhou; Kaiguang Zhang
Journal:  Life (Basel)       Date:  2021-06-03

9.  GREB1L overexpression correlates with prognosis and immune cell infiltration in lung adenocarcinoma.

Authors:  Yilin Yu; Zhiping Wang; Qunhao Zheng; Jiancheng Li
Journal:  Sci Rep       Date:  2021-06-24       Impact factor: 4.379

10.  Zc3h12d, a Novel of Hypomethylated and Immune-Related for Prognostic Marker of Lung Adenocarcinoma.

Authors:  Bo Yang; Lin-Lin Ji; Hong-Liang Xu; Xiao-Ping Li; Hong-Gang Zhou; Ting Xiao; Xiao-He Li; Zhou-Yong Gao; Jian-Zhong Li; Wei-Dong Zhang; Guang-Shun Wang; Ming-Jiang Li
Journal:  J Inflamm Res       Date:  2021-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.